Action Philogen - PHIL

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

20,70

Prix Achat

19,50

Prix Vente

21,00

Volume échangé

3 973

20,40 Fourchette du Jour 21,00

16,50 Plage de 52 semaines 21,90

Cap du marché

836,23M

Clôture Veille

20,90

Ouverture

21,00

Dernière Transaction

20.7

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

8 158

Actions en circulation

40 397 605

Rendement du Dividende

Ratio Cours sur Bénéfices

0,00

Bénéfice par action (BPA)

Chiffre d'affairess

25,12M

Bénéfice net

-6,16M

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.philogen.com

Siège social

Siena, Siena, Ita

Fondé

Philogen Spa est coté dans le secteur Pharmaceutical Preparations de la Italian Stock Exchange avec le ticker PHIL. Le dernier cours de clôture d'Philogen était de 20,90 €. Au cours de la dernière année, les actions de Philogen ont été négociées dans une fourchette de prix de 16,50 € à 21,90 €.

Philogen compte actuellement 40 397 605 actions en circulation. La capitalisation boursière d'Philogen est de 844,31 € million.

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients...

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by...

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for...

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to...

Philogen Announces Clinical Trial Collaboration with MSD

Philogen Announces Clinical Trial Collaboration with MSD The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii...

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in...

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University...

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical...

Philogen Provides Corporate Update

Philogen Provides Corporate Update Philogen Provides Corporate Update Nidlegy™ and Fibromun pivotal clinical trials on track Fibromun shows...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.2	-0.956937799043	20.9	21.3	20.4	8694	20.71522948	DE
4	2.15	11.590296496	18.55	21.3	18.35	11748	19.68026898	DE
12	2.55	14.0495867769	18.15	21.3	16.5	8158	18.77692876	DE
26	0.1	0.485436893204	20.6	21.3	16.5	6339	18.98070941	DE
52	2.7	15	18	21.9	16.5	8105	19.49948387	DE
156	7.18	53.1065088757	13.52	21.9	13	8439	17.33205789	DE
260	3.7	21.7647058824	17	21.9	12.6	11799	16.13489415	DE

PHIL - Frequently Asked Questions (FAQ)

What is the current Philogen share price?

The current share price of Philogen is 20,70 €

How many Philogen shares are in issue?

Philogen has 40 397 605 shares in issue

What is the market cap of Philogen?

The market capitalisation of Philogen is EUR 844,31M

What is the 1 year trading range for Philogen share price?

Philogen has traded in the range of 16,50 € to 21,90 € during the past year

What is the reporting currency for Philogen?

Philogen reports financial results in EUR

What is the latest annual turnover for Philogen?

The latest annual turnover of Philogen is EUR 25,12M

What is the latest annual profit for Philogen?

The latest annual profit of Philogen is EUR -6,16M

What is the registered address of Philogen?

The registered address for Philogen is PIAZZA LA LIZZA, 7, SIENA, SIENA, 53100

What is the Philogen website address?

The website address for Philogen is www.philogen.com

Which industry sector does Philogen operate in?

Philogen operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
1SPCEVirgin Galactic Holdings Inc	3,074 € (19,15%)	924
TDTrenDevice Spa	0,127 € (15,45%)	261k
1LLYLilly Eli and Co	733,60 € (11,46%)	2,05k
1EVTEvotec SE	6,484 € (11,45%)	630
1ENRSiemens Energy AG	64,00 € (10,92%)	22,42k
1UNHUnitedhealth Group Inc	397,90 € (-23,83%)	380
WUBM26Ulisse BioMed SpA	0,11 € (-21,37%)	831
WHIK26Haiki Spa	0,0663 € (-20,88%)	63,49k
FDAFidia	0,0047 € (-14,55%)	37,66M
SFTSoftlab SPA	0,524 € (-10,88%)	4,11k
TITTelecom Italia SpA	0,3213 € (0,09%)	197,12M
ISPIntesa Sanpaolo Spa	4,358 € (-0,88%)	52,8M
FDAFidia	0,0047 € (-14,55%)	37,66M
SPMSaipem Spa	1,8655 € (2,33%)	31,17M
ENELEnel Spa	7,369 € (1,04%)	25,07M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Philogen Spa (PHIL)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Philogen Spa

PHIL Dernières nouvelles

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

Philogen Announces Clinical Trial Collaboration with MSD

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology

Philogen Provides Corporate Update

PHIL - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Philogen Spa (PHIL) Cours

Philogen Spa (PHIL)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Philogen Spa

PHIL Dernières nouvelles

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

Philogen Announces Clinical Trial Collaboration with MSD

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology

Philogen Provides Corporate Update

PHIL - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités